Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

Video

In Partnership With:

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Erin Murphy, MD, radiation oncologist, Cleveland Clinic, discusses the clinical implications of pazopanib (Votrient) plus stereotactic body radiotherapy (SBRT) in pediatric sarcoma.

Findings from a retrospective study of 10 heavily pretreated pediatric patients with metastatic sarcoma, including those with bone, lung, and soft tissue metastases, showed that the combination of pazopanib and SBRT was safe and tolerable.

Having a well-tolerated combination of systemic therapy and localized therapy is important for this heavily pretreated population, says Murphy. These patients tend to be among the most fragile and have typically progressed on at least 2 prior regimens before receiving pazopanib, Murphy explains. Because patients have likely had significant bone marrow suppression, utilizing high-dose SBRT is a good option that doesn’t treat a lot of bone marrow, Murphy concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD